Hoth Therapeutics Inc. recently announced the granting of Japan Country Patent No. 7677628 for its HT-KIT platform. This patent provides protection until August 27, 2039, securing long-term commercial exclusivity. The HT-KIT platform employs splice-switching oligonucleotides to selectively target and disrupt KIT gene expression in mast cells, which are involved in various inflammatory and oncologic conditions. This patent marks a significant step in the global development strategy of HT-KIT, particularly in the Asian market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。